- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04012853
Remotely Supervised tDCS for Persistent Post-traumatic Headache (tDCS for PTH)
March 21, 2023 updated by: VA Office of Research and Development
Remotely Supervised Transcranial Direct Current Stimulation for Persistent Post-traumatic Headache: A Pilot Study
This pilot study is designed to provide preliminary data for a large scale, randomized clinical trial to evaluate the efficacy of remotely administrated at home transcranial Direct Current Stimulation (tDCS) with real-time monitoring via VA Tele-health for persistent post traumatic headache associated with mild traumatic brain injury (mTBI).
Participants will receive total of 20 sessions of tDCS over four weeks.
The investigators anticipate that the results generated from the study will directly translate into immediate meaningful clinical application: not only in management of chronic post traumatic headache, but also in reduction of acute pain medication use, and improving quality of life for our veterans with this debilitating neurological disorder.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The aim of this study is to evaluate the feasibility and efficacy of transcranial Direct Current Stimulation (tDCS) administered at home with real-time monitoring via VA Tele-health for persistent post traumatic headache (PTH) associated with mTBI, and the impact of this treatment on persistent PTH associated functional recovery.
Total of 20 participants (10 treatment group, 10 sham control) will be included in this study.
The investigators will also evaluate recruitment strategies and participants clinical characteristics.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Columbia, South Carolina, United States, 29209
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Verified history of mTBI
- Persistent PTH as defined by International Classification of Headache Disorders (ICHD) III diagnostic criteria("Headache Classification Committee of the International Headache Society (IHS) The ICHD, 3rd Edition 2018).
- Verification of headache frequency through prospectively collected baseline information during the 28-day screening/baseline phase.
- Not currently taking a migraine or headache preventive medication OR has been taking a stable dose of a preventive for at least 60 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.
- The investigators will include medication overuse headache as defined by ICHD III diagnostic criteria.
- Participants is either not of childbearing potential, or if they are of childbearing potential, they agree either to remain abstinent or use (or have their partner use) an acceptable method of birth control for the duration of the study.
- Male or female, age between 20-60 who demonstrates compliance with the electronic Daily Headache Diary during the 28-day baseline phase as defined by entry of headache data on a minimum of 22 to 28 days (80% diary compliance).
Exclusion Criteria:
- Unable to complete headache diary as required by protocol.
- Any psychiatric condition with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in the ability to complete study activities
- Received onabotulinumtoxinA, cognitive behavior therapy, physical therapy or any other form of non-pharmacological therapy for headaches during the 4 months before screening.
- Has a planned military deployment within the 6 months post screening.
- Active substance abuse within last 4 months.
- History of seizure, stroke, multiple sclerosis or other unstable neurological condition or a significant abnormal neurological examination.
- Unable to tolerate tDCS stimulation.
- Have any other conditions that in the judgment of the Investigator would make the participants unsuitable for inclusion or interfere with participating or completing the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment arm
tDCS treatment group
|
Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks.
During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
Other Names:
|
No Intervention: control arm
Sham tDCS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Number of Moderate-to-Severe Headache Days Per Month
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
To evaluate the improvement in numbers of moderate to severe headache days per month from baseline period to end of treatment phase, and to the end of follow-up phase
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Total Number of Headache Days Per Month
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
To evaluate improvement in total number of headache days per month, acute pain mediation used based on number of doses of medication taken from baseline period to end of treatment phase, and to end of follow-up phase in the same cohort.
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Change From Baseline in the Quality of Life Based on Change in Headache Impact Test-6 (HIT-6)
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
To evaluate the impact of headaches on the quality of life measures (pain and disability) based on change in Headache impact test-6 (HIT-6) from baseline period to end of treatment phase, and to end of follow-up phase in persistent PTH.
The six-item Headache Impact Test (HIT-6) provides a global measure of adverse headache impact and was developed to use in screening and monitoring patients with headaches in both clinical practice and clinical research.
A total HIT-6 score ranges from 36 to 78: Little or no impact = HIT-6 score 49 or less; Some impact = HIT-6 score 50-55; Substantial impact = HIT-6 score 56-59; Severe impact = HIT-6 score 60.
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Change From Baseline in the Acute Pain Medication Days Per Month
Time Frame: Change from baseline (four-week daily headache diary) following four-week treatment phase and four week post-treatment follow-up (12 weeks total)
|
change in days of acute pain medication use based on number of days taken during the baseline period to end of the treatment and follow up phase
|
Change from baseline (four-week daily headache diary) following four-week treatment phase and four week post-treatment follow-up (12 weeks total)
|
Number of Participants With a 50% Reduction in Headache Frequency
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Number of participants with 50% or more reduction in monthly headache days (compared to baseline) will be evaluated.
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Change From Baseline in Scores on the Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
assess changes in patient reported depression severity - scale range from 0 to 27, with higher scores indicating more severe depression symptoms
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Change From Baseline in Scores on the DSM-5 PTSD Checklist (PCL-5)
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Assess changes in patient reported PTSD-like symptoms - scale range from 0 to 80, with a lower score suggesting a lower incidence of PTSD
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Change From Baseline in Scores on the Beck's Anxiety Inventory (BAI)
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Assess changes in patient reported anxiety - scale range from 0 to 63, with higher score indicating greater anxiety
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Change From Baseline in Scores on the Rivermead Post-Concussion Questionnaire (RPQ)
Time Frame: Change from baseline following four-week treatment phase and four week post-treatment follow-up (8 weeks total)
|
Assess changes in patient reported concussion-related symptoms - scale range from 0 to 64, with higher scores indicating a worse outcome
|
Change from baseline following four-week treatment phase and four week post-treatment follow-up (8 weeks total)
|
Change From Baseline in Scores on the Insomnia Severity Index (ISI)
Time Frame: Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Assess changes in patient reported insomnia/sleep disturbances - scale range from 0 to 28, with higher scores indicating increased severity of insomnia
|
Baseline (four-week daily headache diary), following four-week treatment phase, and four week post-treatment follow-up (12 weeks total)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 4, 2019
Primary Completion (Actual)
March 31, 2022
Study Completion (Actual)
March 31, 2022
Study Registration Dates
First Submitted
July 2, 2019
First Submitted That Met QC Criteria
July 8, 2019
First Posted (Actual)
July 9, 2019
Study Record Updates
Last Update Posted (Actual)
April 14, 2023
Last Update Submitted That Met QC Criteria
March 21, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Headache Disorders, Primary
- Headache Disorders
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Headache Disorders, Secondary
- Brain Injuries
- Brain Injuries, Traumatic
- Headache
- Tension-Type Headache
- Brain Concussion
- Post-Traumatic Headache
Other Study ID Numbers
- B3194-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Traumatic Brain Injury
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
McGill University Health Centre/Research Institute...UnknownMild Traumatic Brain Injury; ConcussionCanada, France, Israel
-
ElMindA LtdGE HealthcareCompletedTBI (Traumatic Brain Injury) | Mild Traumatic Brain Injury | Concussion, MildUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityHealth Science Center of Xi'an Jiaotong University; The Second Affiliated Hospital...RecruitingMTBI - Mild Traumatic Brain InjuryChina
-
Perception Dynamics InstituteUniversity of California, San Diego; University of South Alabama; University...RecruitingMTBI - Mild Traumatic Brain InjuryUnited States
-
Washington University School of MedicineTerminated
-
Centre Hospitalier de DouaiCompletedCompliance, Patient | Mild Brain Traumatic InjuryFrance
-
Bispebjerg HospitalUniversity of Copenhagen; Synoptik-Fonden; IT University of Copenhagen; The Danish...RecruitingBrain Concussion | mTBI - Mild Traumatic Brain InjuryDenmark
-
Children's National Research InstituteCreare, Inc.RecruitingConcussion | MTBI - Mild Traumatic Brain InjuryUnited States
-
University of CopenhagenRigshospitalet, Denmark; Sygekassernes HelsefondCompletedMild Traumatic Brain Injury | Concussion, MildDenmark
Clinical Trials on transcranial direct current stimulation
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Federal University of ParaíbaCompleted
-
University of Campinas, BrazilUnknownEpilepsy IntractableBrazil
-
Dina Hatem ElhammadyUnknown
-
Shirley Ryan AbilityLabNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Nonfluent AphasiaUnited States
-
University of Texas Rio Grande ValleyRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Federal University of ParaíbaUnknown
-
University of CalgaryAlberta Health servicesRecruitingCervicogenic HeadacheCanada
-
Universidade Federal do Rio Grande do NorteNot yet recruitingLow Back Pain | Transcranial Direct Current Stimulation
-
Nanyang Technological UniversityActive, not recruiting